Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

What will the Covid-19 pandemic look like in 2022?

The Economist’s modelling suggests that covid-19 has killed between 10.8m and 20m people, with a best estimate of 17.3m thus far. In most rich countries vaccines are breaking the link between infections and deaths, and restrictions have eased. In other places, such as eastern Europe, deaths are rising amid a new wave of infections. What should the world expect next year?

The virus will not be eradicated. Only one disease, smallpox, has ever been eliminated. Instead, global immunity will increase as more people are vaccinated or contract covid-19. Some 3.8bn have had at least one jab and 2.8bn are fully vaccinated. Together with those who have caught the disease, around half the world’s population has some level of immunity. Eventually, covid-19 will become endemic: transmission will remain at a steady rate, following seasonal patterns, with fewer spikes in infection. The harm caused may end up somewhere between that of influenza, which kills an estimated 300,000 to 650,000 people annually, and of other coronaviruses, such as the common cold. But endemicity is still a long way off for most countries. Deaths in eastern Europe show the risks in places where vaccination rates remain low. In a best-case scenario, covid-19 could begin to follow a seasonal pattern by 2025. But it will take decades for people to become as immune to it as they are to the common cold.

Source: The Economist

https://www.economist.com/the-economist-explains/2021/11/19/what-will-the-covid-19-pandemic-look-like-in-2022

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!